Is tirzepatide in the surpass lane over GLP-1 receptor agonists for the treatment of diabetes?

The results of ‘Efficacy and Safety of a Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide in Patients with type 2 Diabetes (SURPASS-1): A Double-Blind, Randomised, Phase 3 Trial’ have been published inLancet. doi:10.1016/S0140-6736(21)01324-6.
Source: European Heart Journal - Category: Cardiology Source Type: research